Notice of Intent to Publish a Funding Opportunity Announcement for Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
Notice Number:

Key Dates

Release Date:
Estimated Publication Date of Funding Opportunity Announcement:
August 15, 2022
First Estimated Application Due Date:
October 03, 2022
Earliest Estimated Award Date:
May 01, 2023
Earliest Estimated Start Date:
July 03, 2023
Related Announcements

RFA-CA-21-040 - Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)

Issued by

National Cancer Institute (NCI)


The National Cancer Institute (NCI) intends to promote an initiative by publishing a Funding Opportunity Announcement (FOA) to invite applications for Radiation Oncology-Biology Integration Network (ROBIN) Centers. ROBIN Centers created through this FOA will join an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.

The FOA will utilize the U54 (Specialized Center-Cooperative Agreements) activity code to:

  • Prioritize and support research to test translational hypotheses that advance understanding of mechanistic interactions and biologic consequences of radiation treatment;
  • Support longitudinal collection of clinically annotated research biospecimens prior to (e.g., baseline), during (e.g., on-treatment), and after radiation therapy;
  • Develop a multidisciplinary workforce and engage stakeholders with the expertise to conduct studies in translational and pre-clinical research to best inform clinical radiation oncology studies, including leveraging data science and informatics approaches.

The ROBIN Centers will include human subjects research designated as clinical trials research. The awards we expect to make will support multidimensional, data-dense, small cohort characterization trials of patients receiving standard of care radiation either alone or in a combined modality treatment setting for the cancer(s) of study and will not support clinical trials designed to test for safety or effectiveness of combination treatments. Future clinical trials building on ROBIN Center findings may be supported in a variety of ways, including, but not limited to NCI's Experimental Therapeutics Clinical Trials Network or National Clinical Trials Network.

Collectively, data generated through the ROBIN Centers have potential to set the stage for the cancer research community to move towards a new era of personalized radiation oncology where treatment planning may be optimized in novel ways based on an individual patient’s unique biological signatures to reliably predict radiation-combined modality responses, overcome treatment failure, and mitigate normal tissue toxicities.

Research Initiative Details

This Notice encourages investigators with expertise and insights at the intersection of radiation biology and radiation oncology to begin to consider applying for this reissuance of the ROBIN FOA.

At the foundation of each proposed ROBIN Center is a molecular characterization trial(s) focused on longitudinal collection of biospecimens and multimodal data from a small cohort(s) of patients prior to-, while on-treatment, and after radiotherapy. A successful ROBIN Center will create a research environment with a minimum of two well developed and interrelated research projects with specific aims that directly mesh with the scope and design of the molecular characterization trial. All proposed research projects must be planned with clear potential to longitudinally monitor and assess radiation response dynamics in human patients with the goal of developing a holistic understanding of treatment ramifications in the cancer type(s) and focus area that defines the Center.

Priority research project areas for ROBIN Centers include, but are not limited to:

  • Factors that demarcate characteristics (e.g., functional -omics), heterogeneity, and mechanistic basis of radiation treatment responses in tumor, proximal normal tissue, and distal organ sites;
  • Collection and convergence of data-dense, high-content, multimodal approaches that describe multi-scale longitudinal (e.g., before, on-treatment, and after) radiation response dynamics, which have potential to inform treatment planning or trial design;
  • Distinction of radiation therapy-specific biological responses from combined modality treatments (e.g., chemoradiation) including mechanistic basis for radiation to induce druggable targets and/or use in synthetic lethality approaches;
  • Mechanisms of adaptation to radiation treatment that underlie emergence of resistance, treatment response (success or failure);

Multi-PI and/or multiple institutional applications will be encouraged to maximize the potential of team science efforts and combine capabilities that might be necessary to fulfill the need for highly specialized multidisciplinary research that lies at the intersection of radiation oncology, cancer/radiation biology, and medical physics. Consistent with this, each ROBIN Center shall contain a required Cross-Training Core, designed to foster workforce development and a culture of scientific cross-pollination.

It is anticipated that molecular characterization approaches based on tissue procurement from patients over the course of radiation therapy will be accompanied by orthogonal non-invasive approaches (e.g., imaging, circulating markers, sensor technologies). Studies may be complemented by correlative radiation treatment experiments in established pre-clinical models (e.g., canine, PDX, GEMMs) that directly support testing the overall hypothesis that guides a respective ROBIN Center. Likewise, pre-clinical models with demonstrated relevance to radiation treatment may be leveraged in the initial project period to refine technological innovation and capabilities planned for characterization studies with patient samples, and/or be used to distinguish combined modality responses. Some applicants may offer an arrangement where the putative ROBIN Center’s home institution provides additional complementary support in the form of allied clinical trials, existing cores, and/or industry, national lab partnerships.

Funding Information
Estimated Total Funding

$3.2M per year for five years

Expected Number of Awards


Estimated Award Ceiling

$1M per year in direct costs

Primary Assistance Listing Number(s)

93.393, 93.394, 93.395, 93.396, 93.399

Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government

Applications are not being solicited at this time. 


Please direct all inquiries to:

Michael Graham Espey, Ph.D.

National Cancer Institute (NCI)